An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?
Source: Health Policy - Category: Health Management Authors: Jason Shafrin, Michelle Skornicki, Michelle Brauer, Julie Villeneuve, Michael Lees, Nadine Hertel, John R. Penrod, Jeroen Jansen Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Study